A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults With Alcohol-related Liver Disease (ALD)
Latest Information Update: 03 Oct 2024
At a glance
- Drugs GSK 4532990 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms STARLIGHT
- Sponsors GSK
- 03 Oct 2024 New trial record